OxFORD Asset Management LLP purchased a new stake in shares of Amedisys Inc (NASDAQ:AMED) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 35,827 shares of the health services provider’s stock, valued at approximately $2,250,000. OxFORD Asset Management LLP owned 0.11% of Amedisys as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in Amedisys by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock valued at $70,658,000 after buying an additional 7,963 shares during the period. Parametric Portfolio Associates LLC raised its holdings in Amedisys by 38.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 101,560 shares of the health services provider’s stock valued at $6,379,000 after buying an additional 28,133 shares during the period. Suntrust Banks Inc. raised its holdings in Amedisys by 4.3% during the 2nd quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock valued at $358,000 after buying an additional 237 shares during the period. Sawgrass Asset Management LLC purchased a new stake in Amedisys during the 2nd quarter valued at $1,048,000. Finally, California Public Employees Retirement System raised its holdings in Amedisys by 1.1% during the 2nd quarter. California Public Employees Retirement System now owns 62,300 shares of the health services provider’s stock valued at $3,913,000 after buying an additional 700 shares during the period. Institutional investors own 96.55% of the company’s stock.

In other Amedisys news, insider David B. Pearce sold 1,000 shares of Amedisys stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares in the company, valued at $524,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce D. Perkins bought 2,000 shares of Amedisys stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The disclosure for this purchase can be found here. 2.00% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “35,827 Shares in Amedisys Inc (AMED) Acquired by OxFORD Asset Management LLP” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/35827-shares-in-amedisys-inc-amed-acquired-by-oxford-asset-management-llp/1612546.html.

Several analysts recently weighed in on the company. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Wednesday, July 26th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Robert W. Baird reaffirmed a “hold” rating and issued a $50.00 price objective on shares of Amedisys in a research report on Wednesday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research report on Friday, September 15th. Finally, Bank of America Corporation assumed coverage on Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $55.44.

Amedisys Inc (NASDAQ AMED) opened at 53.47 on Friday. The firm has a 50-day moving average price of $51.97 and a 200 day moving average price of $55.17. The company has a market cap of $1.81 billion, a P/E ratio of 45.70 and a beta of 0.87. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. During the same quarter in the previous year, the business earned $0.42 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities research analysts predict that Amedisys Inc will post $2.21 EPS for the current year.

Amedisys Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.